ViGeneron -Model vgAAV -Vector Platform
FromViGeneron GmbH
vgAAV, ViGeneron’s proprietary AAV Vector platform, is our next generation vector platform based on novel engineered AAV capsids. In a unique in vivo directed-evolution approach we generated our vgAAV vectors. The vgAAV vector platform enables a superior transduction of target cells and is designed to efficiently cross biological barriers. These attributes allow vgAAV vectors to target a broad spectrum of cell types in the retina, thus enabling intravitreal, less invasive treatment administration. vgAAV’s capability to cross biological barriers makes vgAAVs also attractive tools for applications beyond ophthalmology.
Most popular related searches
- Unique: vgAAVs are uniquely engineered AAV capsids with novel properties
- Proprietary: the vgAAV technology is fully owned by ViGeneron
- Efficient: vgAAVs efficiently transduce target cells
- Enabling: vgAAVs overcome biological barriers and enable novel, less invasive routes of administration
- Easy to produce: vgAAVs are easily produced in high yields
- Broadly applicable: vgAAVs are used for ophthalmology programs and have the potential to be applied to other tissues, such as the central nervous system.
